To provide an agent for hypodermic injection that is unlikely to cause inflammation and to provide an injector containing the agent for hypodermic injection.

There is provided a method for producing an agent for hypodermic injection, wherein the agent includes a hydrogel containing sintered hydroxyapatite particles, and the production method includes a deaeration step for removing air contained in the agent.

A skin whitening composition comprising a liquid polymeric coating material that, upon exposure to ambient air and moisture in skin, hardens to a water resistant, water vapor permeable, adherent and conformable solid film when applied to skin, and at least one skin whitening active; and a method and kit for whitening skin.

The present invention concerns a topical, cosmetic or pharmaceutical preparation containing a combination of 3 or 4 solar filters comprising:—one or two UVA filters to obtain a critical wavelength>370 nm, chosen from among: (i)—5,6,5,6-tetraphenyl-3, 3′-(1,4-phenylene)-bis[1,2,4]triazine; (ii) 1,1′-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone; (iii)—Butyl Methoxydibenzoylmethane (BMDBM), in a quantity less than 2% by weight with regard to the total weight of said composition; (iv)—Hexyl-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, -2,4-Bis[4-(2-ethyl-hexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine=(BEMT), —one or two filters chosen from among UVB filters, except octocrylene, PABA and ethylhexyl methoxycinnamate, said composition also containing a pharmaceutically or cosmetically acceptable excipient.

The present invention consists of a novel process for the incorporation of one or more water-soluble active agents in a hydrophilic polymer foam. Said process makes it possible in particular to obtain a hydrophilic polyurethane foam exhibiting a gradient of active agents. This process is of particular use when manufacturing hydrophilic polyurethane foams intended for medical, cosmetic and dermocosmetic purposes.

A cell activator of an animal cell that includes 3H-imidazo[4,5-d][1,2,3]triazine-4,6(5H,7H)-dione.

A cell activator of an animal cell that includes 3H-imidazo[4,5-d][1,2,3]triazine-4,6(5H,7H)-dione.

Disclosed is a method for suppressing adhesion of air harmful substances, including applying an external preparation to skin to suppress adhesion of air pollutants to the skin, wherein the external preparation contains the following component (A) and component (B), and the ratio by mass of the content of the component (A) to the content of the component (B) in the external preparation [(A)/(B)] is 0.30 or more and 5.0 or less. Component (A): a metal oxide having an average primary particle diameter d.sub.A of 800 nm or less. Component (B): non-disintegrable particles having an average particle diameter D.sub.B of 1 μm or more and 10 μm or less.

The instant disclosure provides methods and compositions related to discovery that topical administration of MEK inhibitors for the treatment of skin disorders (e.g., skin cancer, inflammatory skin disorders) is accomplished with markedly reduced dosage levels in comparison with oral administration dosage levels. Therapeutic and/or prophylactic uses and compositions of known MEK inhibitors are described.

The instant disclosure provides methods and compositions related to discovery that topical administration of MEK inhibitors for the treatment of skin disorders (e.g., skin cancer, inflammatory skin disorders) is accomplished with markedly reduced dosage levels in comparison with oral administration dosage levels. Therapeutic and/or prophylactic uses and compositions of known MEK inhibitors are described.

Provided are oxygenated cannabis skin therapy compositions, and methods for preparing the compositions by ozonating coconut oil, extracting medicinal/recreational cannabis into coconut oil to yield a cannabis infused coconut oil, and combining the ozonated coconut oil with the cannabis infused coconut oil to yield the skin therapy compositions.